Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma

Chromosomal translocations affecting the MYC oncogene are the biological hallmark of Burkitt lymphomas but also occur in a subset of other mature B-cell lymphomas. If accompanied by a chromosomal break targeting the BCL2 and/or BCL6 oncogene these MYC translocation-positive (MYC+) lymphomas are called double-hit lymphomas, otherwise the term single-hit lymphomas is applied. In order to characterize the biological features of these MYC+ lymphomas other than Burkitt lymphoma we explored, after exclusion of molecular Burkitt lymphoma as defined by gene expression profiling, the molecular, pathological and clinical aspects of 80 MYC-translocation-positive lymphomas (31 single-hit, 46 double-hit and 3 MYC+-lymphomas with unknown BCL6 status). Comparison of single-hit and double-hit lymphomas revealed no difference in MYC partner (IG/non-IG), genomic complexity, MYC expression or gene expression profile. Double-hit lymphomas more frequently showed a germinal center B-cell-like gene expression profile and had higher IGH and MYC mutation frequencies. Gene expression profiling revealed 130 differentially expressed genes between BCL6+/MYC+ and BCL2+/MYC+ double-hit lymphomas. BCL2+/MYC+ double-hit lymphomas more frequently showed a germinal center B-like gene expression profile. Analysis of all lymphomas according to MYC partner (IG/non-IG) revealed no substantial differences. In this series of lymphomas, in which immunochemotherapy was administered in only a minority of cases, single-hit and double-hit lymphomas had a similar poor outcome in contrast to the outcome of molecular Burkitt lymphoma and lymphomas without the MYC break. Our data suggest that, after excluding molecular Burkitt lymphoma and pediatric cases, MYC+ lymphomas are biologically quite homogeneous with single-hit and double-hit lymphomas as well as IG-MYC and non-IG-MYC+ lymphomas sharing various molecular characteristics.

[1]  J. Briones,et al.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy , 2013, Haematologica.

[2]  R. Spang,et al.  Molecular classification of mature aggressive B-cell lymphoma using digital multiplexed gene expression on formalin-fixed paraffin-embedded biopsy specimens. , 2013, Blood.

[3]  A. Rosenwald,et al.  MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. , 2013, Blood.

[4]  S. Swerdlow,et al.  Double-hit B-cell Lymphomas With BCL6 and MYC Translocations Are Aggressive, Frequently Extranodal Lymphomas Distinct From BCL2 Double-hit B-cell Lymphomas , 2013, The American journal of surgical pathology.

[5]  A. Hagemeijer,et al.  Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B‐cell lymphomas with MYC rearrangement , 2013, Genes, chromosomes & cancer.

[6]  J. Briones,et al.  MYC protein expression and genetic alterations have prognostic impact in diffuse large B-cell lymphoma treated with immunochemotherapy , 2013 .

[7]  R. Spang,et al.  Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing , 2012, Nature Genetics.

[8]  Dereje D. Jima,et al.  The genetic landscape of mutations in Burkitt lymphoma , 2012, Nature Genetics.

[9]  T. Witzig,et al.  Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOP. , 2012, Blood.

[10]  R. Spang,et al.  The cancer stem cell subtype determines immune infiltration of glioblastoma. , 2012, Stem cells and development.

[11]  L. Staudt,et al.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics , 2012, Nature.

[12]  L. Staudt,et al.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Green,et al.  c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.

[14]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[15]  R. Spang,et al.  High myc activity is an independent negative prognostic factor for diffuse large B cell lymphomas , 2012, International journal of cancer.

[16]  K. Young,et al.  Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  A. Rosenwald,et al.  MYC diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation , 2012 .

[18]  M. Routbort,et al.  Prognostic value of MYC rearrangement in cases of B‐cell lymphoma, unclassifiable, with features intermediate between diffuse large B‐cell lymphoma and Burkitt lymphoma , 2012, Cancer.

[19]  A. Bagg,et al.  B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma , 2012 .

[20]  R. Spang,et al.  Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. , 2012, Blood.

[21]  L. Medeiros,et al.  B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome , 2012, Modern Pathology.

[22]  A. Rosenwald,et al.  Follicular lymphoma grade 3B is a distinct neoplasm according to cytogenetic and immunohistochemical profiles , 2011, Haematologica.

[23]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[24]  Dirk Hasenclever,et al.  Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. , 2011, Blood.

[25]  R. Siebert,et al.  The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Philip M Kluin,et al.  Double-hit B-cell lymphomas. , 2011, Blood.

[27]  Ed Schuuring,et al.  Molecular cytogenetics of lymphoma: where do we stand in 2010? , 2011, Histopathology.

[28]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[29]  Michael Hummel,et al.  Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. , 2010, Blood.

[30]  R. Spang,et al.  Detection of genomic aberrations in molecularly defined Burkitt’s lymphoma by array-based, high resolution, single nucleotide polymorphism analysis , 2010, Haematologica.

[31]  R. Siebert Mature B‐ and T‐cell neoplasms and Hodgkin lymphoma , 2010 .

[32]  L. Colomo,et al.  IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas , 2010, The American journal of surgical pathology.

[33]  S. Barrans,et al.  Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  Matija Snuderl,et al.  B-cell Lymphomas With Concurrent IGH-BCL2 and MYC Rearrangements Are Aggressive Neoplasms With Clinical and Pathologic Features Distinct From Burkitt Lymphoma and Diffuse Large B-cell Lymphoma , 2010, The American journal of surgical pathology.

[35]  A. Feller,et al.  BCL6-translocations affect the phenotype of follicular lymphomas only in the absence of t(14;18)IgH/BCL2. , 2009, Anticancer research.

[36]  R. Gascoyne,et al.  MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. , 2009, Blood.

[37]  R. Gascoyne,et al.  Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. , 2009, Blood.

[38]  W. Klapper,et al.  Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphoma , 2009, Haematologica.

[39]  R. Spang,et al.  Microarray‐based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status , 2009, Genes, chromosomes & cancer.

[40]  R. Siebert,et al.  Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge , 2008, Leukemia.

[41]  I. Miura,et al.  Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations , 2009, Leukemia.

[42]  A. Rosenwald,et al.  Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) , 2008, Leukemia.

[43]  L. Staudt,et al.  Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt’s lymphoma , 2008, Haematologica.

[44]  R. Spang,et al.  Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials. , 2008, Blood.

[45]  R. Spang,et al.  Pathway activation patterns in diffuse large B-cell lymphomas , 2008, Leukemia.

[46]  L. Staudt,et al.  Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma , 2007, Leukemia.

[47]  P. Moreau,et al.  The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement , 2007, Haematologica.

[48]  R. Gascoyne,et al.  A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation , 2007, Leukemia.

[49]  F. Jardin,et al.  Mapping of MYC breakpoints in 8q24 rearrangements involving non-immunoglobulin partners in B-cell lymphomas , 2007, Leukemia.

[50]  Richard Simon,et al.  Molecular diagnosis of Burkitt's lymphoma. , 2006, The New England journal of medicine.

[51]  R. Spang,et al.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. , 2006, The New England journal of medicine.

[52]  E. Haralambieva,et al.  Molecular, cytogenetic, and immunophenotypic characterization of follicular lymphoma grade 3B; a separate entity or part of the spectrum of diffuse large B-cell lymphoma or follicular lymphoma? , 2006, Human pathology.

[53]  R. Siebert,et al.  FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. , 2006, The Journal of molecular diagnostics : JMD.

[54]  H. Müller-Hermelink,et al.  Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas With Morphologic Features of Burkitt Lymphoma , 2005, The American journal of surgical pathology.

[55]  Rainer Spang,et al.  twilight; a Bioconductor package for estimating the local false discovery rate , 2005, Bioinform..

[56]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[57]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Zelenetz,et al.  Molecular cytogenetic analysis of genomic instability at the 1q12–22 chromosomal site in B‐cell non‐Hodgkin lymphoma , 2002, Genes, chromosomes & cancer.

[59]  Martin J S Dyer,et al.  Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci , 2002, International journal of cancer.

[60]  R. Gascoyne,et al.  Bcl-3/IgH translocation (14;19)(q32;q13) in Non-Hodgkin's Lymphomas , 2002, Leukemia & lymphoma.

[61]  M. Neuberger,et al.  The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line , 2000, Oncogene.

[62]  R. Siebert,et al.  Clinicopathogenetic significance of chromosomal abnormalities in patients with blastic peripheral B-cell lymphoma. Kiel-Wien-Lymphoma Study Group. , 1999, Blood.

[63]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[64]  G. Gaidano,et al.  Mutations in the coding region of c-myc occur frequently in acquired immunodeficiency syndrome-associated lymphomas. , 1994, Blood.